Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 8Completed 4Withdrawn 3Unknown 3Terminated 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 5CNS 5NET 3Head & Neck 1Dermatologic 1

Conditions

Neuroendocrine Tumors 19Carcinoid Tumor 5Pheochromocytoma 4Paraganglioma 3Gastro-enteropancreatic neuroendocrine tumor 3Vipoma 2Neoplasms 2Insulinoma 2Carcinoma, Merkel Cell 2Zollinger-Ellison Syndrome 1Somatostatinoma 1Small Cell Lung Carcinoma 1Serotonin Syndrome 1Pancreatic Neoplasms 1Non functioning pancreatic endocrine tumor 1Neuroblastoma 1Neoplasms, Unknown Primary 1Neoplasms, Cystic, Mucinous, and Serous 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Liver Neoplasms 1Hypoglycemia 1Glucagonoma 1Gastrinoma 1Diarrhea 1Carcinoma, Medullary 1Cachexia 1Adrenal Gland Neoplasms 1

Interventions

vandetanib 1lutetium Lu 177 dotatate 13-Iodobenzylguanidine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Paraganglioma × NET × Clear all
NCT04276597 2023-03-10

PUTNET

Excel Diagnostics and Nuclear Oncology Center

Phase 2 Withdrawn
CNSDermatologicEndocrineNET

Neoplasms, Unknown Primary, Paraganglioma, Pheochromocytoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT03923257 2021-06-08

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents

University of Iowa

Phase 1/2 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT01941849 2015-12-21

VIBRaNT

University College, London

Phase 1 Withdrawn
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡